Bictegravir

證據等級: L5

預測適應症: 3 個

Bictegravir: From HIV-1 Infection to Feline Acquired Immunodeficiency Syndrome (Feline AIDS)

One-Sentence Summary

Bictegravir is an HIV-1 integrase strand transfer inhibitor (INSTI), used clinically as part of antiretroviral therapy in people living with HIV. The TxGNN model predicts it may be effective against feline acquired immunodeficiency syndrome (a lentiviral disease in cats caused by FIV), with a very high prediction score but no clinical trials or literature currently supporting this specific indication. A closely related, identically-scored prediction — simian immunodeficiency virus (SIV) infection — is supported by 3 mechanistic/preclinical publications and is discussed below as corroborating evidence for the same biological hypothesis (lentiviral integrase inhibition).

Quick Overview

Item	Content
Original Indication	HIV-1 infection (inferred from literature evidence in this pack; TFDA-approved indication text not yet available — see Data Gap DG001)
Predicted New Indication	Feline Acquired Immunodeficiency Syndrome (Feline AIDS)
TxGNN Prediction Score	99.82%
Evidence Level	L5 (model prediction only — no clinical trials or literature specific to this indication)
Germany Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data for bictegravir is not yet available in this evidence pack (Data Gap DG002). Based on the literature evidence retrieved, bictegravir is a second-generation integrase strand transfer inhibitor (INSTI) used in combination antiretroviral therapy for HIV-1, and it imparts a high genetic barrier to resistance compared to earlier INSTIs such as raltegravir and elvitegravir.

Feline AIDS is caused by feline immunodeficiency virus (FIV), a lentivirus in the same retroviral family as HIV, sharing a homologous integrase enzyme mechanism. This provides a plausible mechanistic rationale for TxGNN's prediction — an integrase inhibitor effective against one lentivirus may plausibly inhibit integration of a related lentivirus. However, no clinical trials, ICTRP trials, or published literature directly evaluate bictegravir in FIV/feline AIDS, so this remains a mechanism-only hypothesis (Evidence Level L5).

Notably, TxGNN assigned an identical score (99.82%) to a second, closely related prediction: simian immunodeficiency virus (SIV) infection. Unlike feline AIDS, this prediction is supported by 3 publications describing bictegravir's antiviral activity against SIV and SIV/HIV intasome structural biology, effectively corroborating the underlying mechanistic hypothesis (cross-lentivirus integrase inhibition) even though the pack does not provide feline-AIDS-specific data. This supporting literature is presented below.

Clinical Trial Evidence

Currently no related clinical trials registered for feline acquired immunodeficiency syndrome (or for the related SIV infection prediction).

Literature Evidence

No literature is directly indexed against feline AIDS in this pack. The following 3 publications support the closely related, identically-scored prediction (SIV infection), and are included here as mechanistic corroboration for the cross-lentivirus integrase-inhibition hypothesis:

PMID	Year	Type	Journal	Key Findings
28923862	2017	Preclinical/Mechanism	Antimicrobial Agents and Chemotherapy	Bictegravir shows antiviral activity against integrase-inhibitor-resistant SIVmac239 and HIV-1, with a higher genetic barrier to resistance than raltegravir/elvitegravir
32506843	2021	Review/Structural biology	The FEBS Journal	Structural analysis of HIV/SIV intasome complexes explains bictegravir binding and viral escape mechanisms
39559349	2024	Preclinical (animal model)	Frontiers in Immunology	Humanized mouse model developed for testing antiretroviral strategies against both SIV and HIV

Germany Market Information

Bictegravir currently has no marketing authorizations on record (market status: Not Marketed, 0 licenses). No authorization table can be generated.

Safety Considerations

Safety data (key warnings, contraindications, drug interactions) are not yet available for this candidate. This is flagged as a Blocking data gap (DG001 — TFDA labeling warnings/contraindications), which currently prevents entry into S1 safety pre-assessment. Please refer to the package insert for safety information once available.

Note: Screened-Out Prediction (Not Pursued)

A third TxGNN prediction in this pack — a rare neurodevelopmental disorder (ataxic gait, absent speech, decreased cortical white matter) — was already scored by the pipeline as L5 / S0 / Hold, with the rationale that this genetic neurodevelopmental condition has no known pathological link to viral integrase inhibition and no supporting trials or literature. It is treated as a likely false-positive TxGNN output and is excluded from further consideration.

Conclusion and Next Steps

Decision: Hold

Rationale: The feline AIDS prediction is mechanistically plausible (lentivirus integrase homology) and reinforced by literature on the closely related SIV prediction, but it has zero indication-specific clinical or literature evidence, no confirmed original-indication regulatory text, and no German market authorization. Most critically, the Blocking safety data gap (DG001) prevents any S1 safety pre-assessment.

To proceed, the following is needed:

TFDA/BfArM label warnings and contraindications (resolve DG001, currently Blocking)
Confirmed mechanism-of-action documentation from DrugBank (resolve DG002)
Confirmation of original approved indication text (HIV-1 infection) from a regulatory source
Any veterinary or preclinical efficacy data specific to FIV/feline AIDS, if this candidate is to be pursued as a veterinary repurposing case rather than purely as a human-medicine hypothesis
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.